Centogene N.V.

Equities

CNTG

NL0014040206

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-20 pm EDT			5-day change	1st Jan Change
0.3806 ^USD	+2.86%		-4.83%	-68.28%

May. 16	Upcoming Slew of Economic Data Buoys Exchange-Traded Funds, Equity Futures Pre-Bell Thursday	MT
May. 16	Top Premarket Gainers	MT

Centogene N.V. Provides Revenue Guidance for the Second Half and Full Year of 2021

September 07, 2021 at 06:35 am EDT

Centogene N.V. provides revenue guidance for the second half and full year of 2021. For the half, The company anticipates COVID-19 revenues to decline. For the year, the company expects overall revenue to surpass fiscal year 2020.

Latest news about Centogene N.V.

Upcoming Slew of Economic Data Buoys Exchange-Traded Funds, Equity Futures Pre-Bell Thursday	May. 16	MT
Top Premarket Gainers	May. 16	MT
Centogene N.V. Provides Earnings Guidance for the Year 2024	May. 15	CI
Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment	May. 14	MT
Centogene N.V and Evotec SE Discovers Promising New Molecule to Treat Gaucher Disease	May. 14	CI
Centogene Biodatabank Grows to Incorporate Disease Insights from over 850,000 Diverse Patients	May. 10	CI
Centogene Gets Nasdaq Noncompliance Notice	Apr. 02	MT
Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics	Mar. 19	MT
Centogene N.V. Announces the Extension of an Ongoing Partnership with Takeda to Continue Providing Access to Genetic Testing for Patients with Lysosomal Storage Disorders	Mar. 19	CI
Centogene Explores Strategic Alternatives	Feb. 27	CI
Centogene N.V. and the Laboratory of Human Genetics of Infectious Diseases At Institut Imagine Announce Rare Disease Research Collaboration	Jan. 25	CI
Centogene N.V. and The Michael J. Fox Foundation for Parkinson's Research Announces Research Project to Validate Genetic Risk Factors of Parkinson's Disease Using Multiomics	Jan. 23	CI
Centogene N.V. Provides Earnings Guidance for the Full Year 2023	Jan. 18	CI
Centogene N.V. Announces Changes to Supervisory Board	Dec. 18	CI
Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone	Dec. 13	CI
Centogene, Saudi Arabia's Public Investment Fund Form JV	Nov. 28	MT
Centogene N.V. and Lifera Complete Strategic Joint Venture Transaction	Nov. 28	CI
Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism	Nov. 14	CI
Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering	23-10-10	CI
Flemming Ornskov Decides to Step Down from His Role as a Member of the Supervisory Board of Centogene	23-10-06	CI
Centogene N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-07	CI
Centogene N.V. Reaffirms Revenue Guidance for the Year 2023	23-09-07	CI
Upcoming Payrolls Report Lifts Exchange-Traded Funds, Equity Futures Premarket Friday	23-09-01	MT
Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients	23-09-01	CI
Centogene Receives Non-Compliance Notice From Nasdaq	23-09-01	MT

Chart Centogene N.V.

Duration

Period

More charts

Company Profile

Centogene N.V., is a commercial company. The company focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The company's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Company's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.

Sector

Biotechnology & Medical Research

Calendar

2024-06-16 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Centogene N.V.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.3504 EUR

Average target price

1.378 EUR

Spread / Average Target

+293.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CENTOGENE N.V.	-68.28%	10.31M
MODERNA, INC.	+41.79%	50.93B
IQVIA HOLDINGS INC.	-0.56%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-7.20%	29.18B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	18.9B
BIO-TECHNE CORPORATION	+6.92%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.17B
MEDPACE HOLDINGS, INC.	+29.60%	12.16B

Other Biotechnology & Medical Research